![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Wuxi Fortune Pharmaceutical Co., Ltd. Wuxi Cn, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Mycophenolate mofetil, Process 2, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2019-159 - Rev 00
This Chemical Type CEP, issued on November 30, 2020, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1700 associated with this CEP further emphasizes